225 Actinium PSMA Therapy for Metastatic Prostate Cancer | Minute Medical, Vienna

At Minute Medical in Vienna, we provide a pioneering frontier in nuclear medicine: 225-Actinium (Ac-225) PSMA therapy. This advanced "Targeted Alpha Therapy" (TAT) is specifically designed for patients with metastatic castration-resistant prostate cancer (mCRPC) who have exhausted conventional treatments or for whom 177-Lutetium therapy is no longer effective. Located in the heart of Vienna, Minute Medical combines an ultra-modern outpatient setting with the highly specialized radiopharmaceutical expertise required to handle alpha-emitters, offering a potent second-line biological weapon against advanced malignancy. The therapeutic power of 225-Actinium lies in its high "linear energy transfer. " Unlike standard beta-emitters (like Lutetium), which travel several millimeters through tissue, Actinium-225 emits alpha particles that travel a distance of less than 0. 1 millimeters - roughly the width of a few cells. This ensures that the radiation energy is deposited with extreme density directly into the tumor cell, causing irreversible double-strand DNA breaks. Because the reach is so short, the surrounding healthy tissue, particularly the bone marrow, is spared from significant radiation exposure. At Minute Medical, we use this "molecular scalpel" to target the prostate-specific membrane antigen (PSMA) found on nearly all prostate cancer cells, regardless of where they have metastasized in the body. The treatment process at Minute Medical is characterized by a personalized, high-precision protocol. Before therapy begins, we perform a PSMA PET/CT to create a detailed "map" of all tumor sites and confirm that the cancer cells are expressing the target receptor. The Ac-225 is then administered via a simple intravenous injection. Once in the bloodstream, the Actinium molecules seek out and bind to the PSMA receptors like a key in a lock. The procedure is conducted in a comfortable, specialized environment under the supervision of our nuclear medicine experts, ensuring that every patient receives a dose calculated specifically for their tumor load and kidney function. Recovery and post-treatment monitoring at our Vienna clinic are designed to be as non-intrusive as possible. Because alpha radiation has such a short range, it does not exit the patient's body in a way that poses a risk to others, allowing for a more flexible post-injection period compared to traditional radiation. Patients remain at Minute Medical for a few hours of observation to ensure optimal hydration and well-being.